Octagon Capital Advisors LP Cyma Bay Therapeutics, Inc. Transaction History

Octagon Capital Advisors LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.63 - $24.47 $24 Million - $46.4 Million	-1,897,168 Reduced 41.51%	2,673,750 $63.2 Million
Q1 2023 May 15, 2023	BUY	$5.88 - $9.59 $15.9 Million - $26 Million	2,711,718 Added 145.85%	4,570,918 $39.9 Million
Q4 2022 Feb 14, 2023	BUY	$3.22 - $6.27 $5.99 Million - $11.7 Million	1,859,200 New	1,859,200 $11.7 Million

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Octagon Capital Advisors LP with notifications on news.